Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2

BACKGROUNDAnastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Translational andrology and urology 2021-03, Vol.10 (3), p.1222-1228
Hauptverfasser:	Shah, Tejash, Nyirenda, Themba, Shin, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1228
container_issue	3
container_start_page	1222
container_title	Translational andrology and urology
container_volume	10
creator	Shah, Tejash Nyirenda, Themba Shin, David
description	BACKGROUNDAnastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio
doi_str_mv	10.21037/tau-20-919
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512737639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-cae195cbabb8e72b9643980afbf58fa717c49ad5a866bee74d4a5615a3eda80d3</originalsourceid><addsrcrecordid>eNpVkc1u1TAQhS1E1Valq76Al0gQ6p84tjdIqCo_UiU2dG2NnfFNIIkvtkO5vAEPwovxJARaVWI1I51vzhzpEHLB2SvBmdSXFdZGsMZy-4ScCiFk03aWP33cjTwh56V8ZoxxIU3b8WNyIqVRTCt9SobrGMcA4UBTpLBAqTn9SBPScaF1QFozQp1xqX_14bBPu7RAD9NLWlYfMddxYzed3o11oD71BzpDKdt5j9_p75-_hKJfdpezeEaOIkwFzx_mGbl9e_3p6n1z8_Hdh6s3N00QxtQmAHKrggfvDWrhbddKaxhEH5WJoLkOrYVegek6j6jbvgXVcQUSezCsl2fk9b3vfvUz9mGLnmFy-zzOkA8uwej-V5ZxcLv0zRkmbcfkZvD8wSCnryuW6uaxBJwmWDCtxQnFhZa6k3ZDX9yjIadSMsbHN5y5f_W4rR4nmNvqkX8AqRqErA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512737639</pqid></control><display><type>article</type><title>Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shah, Tejash ; Nyirenda, Themba ; Shin, David</creator><creatorcontrib>Shah, Tejash ; Nyirenda, Themba ; Shin, David</creatorcontrib><description><![CDATA[BACKGROUNDAnastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio <10 in order to increase endogenous testosterone levels. This study sought to evaluate the efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index greater than 25 mg/kg2 with respect to hormonal profile, semen parameters and overall fertility status. METHODSRetrospective chart review was performed of hypogonadal, subfertile men with body mass index ≥25 kg/m2 who were treated with anastrozole (1 mg daily). Hormonal measurements and semen analysis prior to and after treatment was analyzed in 30 men. Total motile count was calculated from semen analysis. Clinical pregnancy rates were recorded. RESULTSMen treated with anastrozole had increases in follicle stimulating hormone (4.8 versus 7.6 IU/L, P<0.0001), luteinizing hormone (3.4 versus 5.4 IU/L, P<0.0001), testosterone (270.6 versus 412 ng/dL, P<0.0001) and testosterone-to-estradiol ratio (9 versus 26.5, P<0.0001) and decrease in estradiol level (32 versus 15.9 pg/mL, P<0.01) after 5 months of therapy. Increases in sperm concentration (7.8 versus 14.2 million/mL, P<0.001), total motile count (12.6 versus 17.7 million, P<0.01) and strict morphology (3.0% versus 3.5%, P<0.05) was appreciated. Clinical pregnancy rate for our cohort was 46.6% (14 of 30), with 71.4% (10 of 14) conceiving through in vitro fertilization, 14.2% (2 of 14) through intrauterine insemination and 14.2% (2 of 14) through natural intercourse. CONCLUSIONSAnastrozole improves hormonal profiles and semen parameters in hypogonadal, subfertile men with body mass index over 25 kg/m2 and may aid in achieving pregnancy especially in conjunction with assisted reproductive techniques.]]></description><identifier>ISSN: 2223-4683</identifier><identifier>ISSN: 2223-4691</identifier><identifier>EISSN: 2223-4691</identifier><identifier>DOI: 10.21037/tau-20-919</identifier><identifier>PMID: 33850757</identifier><language>eng</language><publisher>AME Publishing Company</publisher><subject>Original</subject><ispartof>Translational andrology and urology, 2021-03, Vol.10 (3), p.1222-1228</ispartof><rights>2021 Translational Andrology and Urology. All rights reserved. 2021 Translational Andrology and Urology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c288t-cae195cbabb8e72b9643980afbf58fa717c49ad5a866bee74d4a5615a3eda80d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039603/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039603/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Shah, Tejash</creatorcontrib><creatorcontrib>Nyirenda, Themba</creatorcontrib><creatorcontrib>Shin, David</creatorcontrib><title>Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2</title><title>Translational andrology and urology</title><description><![CDATA[BACKGROUNDAnastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio <10 in order to increase endogenous testosterone levels. This study sought to evaluate the efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index greater than 25 mg/kg2 with respect to hormonal profile, semen parameters and overall fertility status. METHODSRetrospective chart review was performed of hypogonadal, subfertile men with body mass index ≥25 kg/m2 who were treated with anastrozole (1 mg daily). Hormonal measurements and semen analysis prior to and after treatment was analyzed in 30 men. Total motile count was calculated from semen analysis. Clinical pregnancy rates were recorded. RESULTSMen treated with anastrozole had increases in follicle stimulating hormone (4.8 versus 7.6 IU/L, P<0.0001), luteinizing hormone (3.4 versus 5.4 IU/L, P<0.0001), testosterone (270.6 versus 412 ng/dL, P<0.0001) and testosterone-to-estradiol ratio (9 versus 26.5, P<0.0001) and decrease in estradiol level (32 versus 15.9 pg/mL, P<0.01) after 5 months of therapy. Increases in sperm concentration (7.8 versus 14.2 million/mL, P<0.001), total motile count (12.6 versus 17.7 million, P<0.01) and strict morphology (3.0% versus 3.5%, P<0.05) was appreciated. Clinical pregnancy rate for our cohort was 46.6% (14 of 30), with 71.4% (10 of 14) conceiving through in vitro fertilization, 14.2% (2 of 14) through intrauterine insemination and 14.2% (2 of 14) through natural intercourse. CONCLUSIONSAnastrozole improves hormonal profiles and semen parameters in hypogonadal, subfertile men with body mass index over 25 kg/m2 and may aid in achieving pregnancy especially in conjunction with assisted reproductive techniques.]]></description><subject>Original</subject><issn>2223-4683</issn><issn>2223-4691</issn><issn>2223-4691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkc1u1TAQhS1E1Valq76Al0gQ6p84tjdIqCo_UiU2dG2NnfFNIIkvtkO5vAEPwovxJARaVWI1I51vzhzpEHLB2SvBmdSXFdZGsMZy-4ScCiFk03aWP33cjTwh56V8ZoxxIU3b8WNyIqVRTCt9SobrGMcA4UBTpLBAqTn9SBPScaF1QFozQp1xqX_14bBPu7RAD9NLWlYfMddxYzed3o11oD71BzpDKdt5j9_p75-_hKJfdpezeEaOIkwFzx_mGbl9e_3p6n1z8_Hdh6s3N00QxtQmAHKrggfvDWrhbddKaxhEH5WJoLkOrYVegek6j6jbvgXVcQUSezCsl2fk9b3vfvUz9mGLnmFy-zzOkA8uwej-V5ZxcLv0zRkmbcfkZvD8wSCnryuW6uaxBJwmWDCtxQnFhZa6k3ZDX9yjIadSMsbHN5y5f_W4rR4nmNvqkX8AqRqErA</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Shah, Tejash</creator><creator>Nyirenda, Themba</creator><creator>Shin, David</creator><general>AME Publishing Company</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202103</creationdate><title>Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2</title><author>Shah, Tejash ; Nyirenda, Themba ; Shin, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-cae195cbabb8e72b9643980afbf58fa717c49ad5a866bee74d4a5615a3eda80d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Tejash</creatorcontrib><creatorcontrib>Nyirenda, Themba</creatorcontrib><creatorcontrib>Shin, David</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational andrology and urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Tejash</au><au>Nyirenda, Themba</au><au>Shin, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2</atitle><jtitle>Translational andrology and urology</jtitle><date>2021-03</date><risdate>2021</risdate><volume>10</volume><issue>3</issue><spage>1222</spage><epage>1228</epage><pages>1222-1228</pages><issn>2223-4683</issn><issn>2223-4691</issn><eissn>2223-4691</eissn><abstract><![CDATA[BACKGROUNDAnastrozole is a non-steroidal fourth generation aromatase inhibitor that stops the conversion of testosterone to estradiol and has been used as empiric medical therapy for the treatment of male infertility in men with an abnormal testosterone-to-estradiol ratio <10 in order to increase endogenous testosterone levels. This study sought to evaluate the efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index greater than 25 mg/kg2 with respect to hormonal profile, semen parameters and overall fertility status. METHODSRetrospective chart review was performed of hypogonadal, subfertile men with body mass index ≥25 kg/m2 who were treated with anastrozole (1 mg daily). Hormonal measurements and semen analysis prior to and after treatment was analyzed in 30 men. Total motile count was calculated from semen analysis. Clinical pregnancy rates were recorded. RESULTSMen treated with anastrozole had increases in follicle stimulating hormone (4.8 versus 7.6 IU/L, P<0.0001), luteinizing hormone (3.4 versus 5.4 IU/L, P<0.0001), testosterone (270.6 versus 412 ng/dL, P<0.0001) and testosterone-to-estradiol ratio (9 versus 26.5, P<0.0001) and decrease in estradiol level (32 versus 15.9 pg/mL, P<0.01) after 5 months of therapy. Increases in sperm concentration (7.8 versus 14.2 million/mL, P<0.001), total motile count (12.6 versus 17.7 million, P<0.01) and strict morphology (3.0% versus 3.5%, P<0.05) was appreciated. Clinical pregnancy rate for our cohort was 46.6% (14 of 30), with 71.4% (10 of 14) conceiving through in vitro fertilization, 14.2% (2 of 14) through intrauterine insemination and 14.2% (2 of 14) through natural intercourse. CONCLUSIONSAnastrozole improves hormonal profiles and semen parameters in hypogonadal, subfertile men with body mass index over 25 kg/m2 and may aid in achieving pregnancy especially in conjunction with assisted reproductive techniques.]]></abstract><pub>AME Publishing Company</pub><pmid>33850757</pmid><doi>10.21037/tau-20-919</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2223-4683
ispartof	Translational andrology and urology, 2021-03, Vol.10 (3), p.1222-1228
issn	2223-4683 2223-4691 2223-4691
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039603
source	Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects	Original
title	Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m2
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A54%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20anastrozole%20in%20the%20treatment%20of%20hypogonadal,%20subfertile%20men%20with%20body%20mass%20index%20%E2%89%A525%20kg/m2&rft.jtitle=Translational%20andrology%20and%20urology&rft.au=Shah,%20Tejash&rft.date=2021-03&rft.volume=10&rft.issue=3&rft.spage=1222&rft.epage=1228&rft.pages=1222-1228&rft.issn=2223-4683&rft.eissn=2223-4691&rft_id=info:doi/10.21037/tau-20-919&rft_dat=%3Cproquest_pubme%3E2512737639%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512737639&rft_id=info:pmid/33850757&rfr_iscdi=true